Literature DB >> 19168156

Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages.

Xuemei Zhang1, Yu Song, Huanzhang Xiong, Xinxin Ci, Hongyu Li, Lu Yu, Lei Zhang, Xuming Deng.   

Abstract

We have previously shown that ivermectin inhibits LPS-induced production of inflammatory cytokines. In the present study, we investigated the effect of ivermectin on lipopolysaccharide (LPS)-induced nitric oxide (NO) and prostaglandin E(2) (PGE(2)) production in RAW 264.7 macrophages. Ivermectin inhibited LPS-induced NO and PGE(2) production. Consistent with these observations, the protein and mRNA expression levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) enzymes were inhibited by ivermectin in a concentration-dependent manner. Furthermore, the phosphorylation of p38, ERK1/2, and JNK in LPS-stimulated RAW 264.7 cells was suppressed by ivermectin in a dose-dependent manner. These results suggest that ivermectin suppresses NO and PGE(2) production, as well as iNOS and COX-2 expression, by inhibiting phosphorylation of mitogen-activated protein kinases (MAPK) (p38, ERK1/2, and JNK) in LPS-stimulated RAW 264.7 cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19168156     DOI: 10.1016/j.intimp.2008.12.016

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  15 in total

1.  Anti-inflammatory effects of ivermectin in mouse model of allergic asthma.

Authors:  Shuhan Yan; Xinxin Ci; Na Chen; Chi Chen; Xiangchao Li; Xiao Chu; Jianhua Li; Xuming Deng
Journal:  Inflamm Res       Date:  2011-01-29       Impact factor: 4.575

Review 2.  Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?

Authors:  David Brown
Journal:  Nat Rev Drug Discov       Date:  2015-10-23       Impact factor: 84.694

3.  Possible Role of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Recovery of Post-COVID-19 Anosmia.

Authors:  Zaki F Aref; Shamardan Ezz Eldin S Bazeed; Mohammed H Hassan; Abeer S Hassan; Ali A Ghweil; Mennatallah Ali Abdelrhman Sayed; Alaa Rashad; Haggagy Mansour; Aida A Abdelmaksoud
Journal:  Infect Drug Resist       Date:  2022-09-19       Impact factor: 4.177

4.  Potential therapeutic effects of Ivermectin in COVID-19.

Authors:  Nastaran Barati; Seyedmousa Motavallihaghi; Banafsheh Nikfar; Shahla Chaichian; Amir Abbas Momtazi-Borojeni
Journal:  Exp Biol Med (Maywood)       Date:  2022-06-10

5.  Non-effectiveness of Ivermectin on Inpatients and Outpatients With COVID-19; Results of Two Randomized, Double-Blinded, Placebo-Controlled Clinical Trials.

Authors:  Mohammad Sadegh Rezai; Fatemeh Ahangarkani; Andrew Hill; Leah Ellis; Manya Mirchandani; Alireza Davoudi; Gohar Eslami; Fatemeh Roozbeh; Farhang Babamahmoodi; Nima Rouhani; Ahmad Alikhani; Narges Najafi; Roya Ghasemian; Hossein Mehravaran; Azin Hajialibeig; Mohammad Reza Navaeifar; Leila Shahbaznejad; Golnar Rahimzadeh; Majid Saeedi; Reza Alizadeh-Navai; Mahmood Moosazadeh; Shahab Saeedi; Seyedeh-Kiana Razavi-Amoli; Shaghayegh Rezai; Fereshteh Rostami-Maskopaee; Fatemeh Hosseinzadeh; Faezeh Sadat Movahedi; John S Markowitz; Reza Valadan
Journal:  Front Med (Lausanne)       Date:  2022-06-16

Review 6.  Ivermectin: An Anthelmintic, an Insecticide, and Much More.

Authors:  Richard J Martin; Alan P Robertson; Shivani Choudhary
Journal:  Trends Parasitol       Date:  2020-11-11

Review 7.  Topical Ivermectin 10 mg/g and Oral Doxycycline 40 mg Modified-Release: Current Evidence on the Complementary Use of Anti-Inflammatory Rosacea Treatments.

Authors:  Martin Steinhoff; Marc Vocanson; Johannes J Voegel; Feriel Hacini-Rachinel; Gregor Schäfer
Journal:  Adv Ther       Date:  2016-07-18       Impact factor: 3.845

8.  New indications for topical ivermectin 1% cream: a case series study.

Authors:  Wioletta Barańska-Rybak; Elżbieta Kowalska-Olędzka
Journal:  Postepy Dermatol Alergol       Date:  2019-02-22       Impact factor: 1.837

9.  Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19.

Authors:  James J DiNicolantonio; Jorge Barroso; Mark McCarty
Journal:  Open Heart       Date:  2020-09

10.  Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment.

Authors:  Na Li; Lingfeng Zhao; Xianquan Zhan
Journal:  J Cell Physiol       Date:  2020-09-22       Impact factor: 6.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.